@article{37b1211f7e8b41b1bd3f5992ddef4bcd,
title = "Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar i or II disorder: Results from the Bipolar CHOICE trial",
abstract = "Background Little is known about the longer-term effects of adjunctive benzodiazepines on symptom response during treatment in patients with bipolar disorders. Methods The study sample consisted of 482 patients with bipolar I or II disorder enrolled in a 6-month, randomized, multi-site comparison of lithium- and quetiapine-based treatment. Changes in clinical measures (BISS total and subscales, CGI-BP, and CGI-Efficacy Index) were compared between participants who did and did not receive benzodiazepine treatment at baseline or during follow-up. Selected outcomes were also compared between patients who did and did not initiate benzodiazepines during follow-up using stabilized inverse probability weighted analyses. Results Significant improvement in all outcome measures occurred within each benzodiazepine exposure group. Benzodiazepine users (at baseline or during follow-up) experienced significantly less improvement in BISS total, BISS irritability, and CGI-BP scores than did benzodiazepine non-users. There were no significant differences in these measures between patients who did and did not initiate benzodiazepines during follow-up in the weighted analyses. There was no significant effect of benzodiazepine use on any outcome measure in patients with comorbid anxiety or substance use disorders. Limitations This is a secondary analysis of data from a randomized effectiveness trial that was not designed to address differential treatment response according to benzodiazepine use. Conclusions Adjunctive benzodiazepines may not significantly affect clinical outcome in lithium- or quetiapine-treated patients with bipolar I or II disorder over 6 months, after controlling for potential confounding factors.",
keywords = "Benzodiazepines, Bipolar disorder, Clinical outcome, Lithium, Quetiapine",
author = "Bobo, {William V.} and Reilly-Harrington, {Noreen A.} and Ketter, {Terence A.} and Brody, {Benjamin D.} and Gustavo Kinrys and Kemp, {David E.} and Shelton, {Richard C.} and McElroy, {Susan L.} and Sylvia, {Louisa G.} and Kocsis, {James H.} and McInnis, {Melvin G.} and Friedman, {Edward S.} and Vivek Singh and Mauricio Tohen and Bowden, {Charles L.} and Thilo Deckersbach and Calabrese, {Joseph R.} and Thase, {Michael E.} and Nierenberg, {Andrew A.} and Rabideau, {Dustin J.} and Schoenfeld, {David A.} and Faraone, {Stephen V.} and Masoud Kamali",
note = "Funding Information: Dr. Brody has received salary support over the past 3 years from Grants funded by Forrest, Agency for Healthcare Quality and Research , and Pritzker Neuropsychiatric Disorders Research Consortium . Funding Information: Dr. McInnis has received Grants for research support from NIMH , the Heinz C Prechter Research Fund , and the Michigan Institute for Clinical Health Research (MICHR). MM has received consulting income from the Qatar National Research Foundation and Merck Pharmaceuticals. Funding Information: Dr. Shelton has served as a consultant to Bristol-Myers Squibb, Cyberonics, Inc., Elan, Corp., Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Medtronic, Inc., Otsuka Pharmaceuticals, Pamlab, Inc., Pfizer, Inc., Ridge Diagnostics, Takeda Pharmaceuticals. Dr. Shelton has received research Grant support from Appian Labs , Bristol‐Myers Squibb Foundation , Elan, Corp. , Eli Lilly and Company , Euthymics Bioscience , Forest Pharmaceuticals , Janssen Pharmaceutica , Naurex, Inc. , Novartis Pharmaceuticals, Otsuka Pharmaceuticals , Pamlab, Inc. , Repligen, Corp. , Ridge Diagnostics , St. Jude Medical Inc., Takeda Pharmaceuticals . Funding Information: Dr. Friedman r eceives Grant support from Repligen , AstraZeneca , Roche , Takeda , Neosync . He has been a consultant for Pamlab. He receives royalties from Springer. He has served as an expert forensic consultant for Thomson Rhodes & Cowie P.C. and Berger and Zavesky Co. L.P.A. Funding Information: Dr. Kocsis has received research Grants and contracts from AHRQ , NIMH , NIDA , Burroughs Wellcome Fund , Pritzker Consortium , Takeda , Forest , AstraZeneca , Roche . He is on the speaker′s bureau at Pfizer and Merck and on the advisory board at Corcept. Funding Information: Dr. Freedman received Grant support from NIMH , AHRQ , Novartis , St. Jude Medical , Medtronics , Repligen , AstraZeneca , Roche , and Takeda . He receives royalties from Springer. He has been a consultant for PamLab. ",
year = "2014",
month = jun,
day = "1",
doi = "10.1016/j.jad.2014.02.046",
language = "English (US)",
volume = "161",
pages = "30--35",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
}